NDA 208653 · Zevra Therap
Apadaz
Acetaminophen, Benzhydrocodone Hydrochloride · Oral
Priority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 31, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Feb 23, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,695
325 Phase 3, 144 recruiting
FAERS reports
21
15 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF APADAZ Addiction, Abuse, and Misuse Because the use of APADAZ exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of APADAZ, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of APADAZ are essential [see Warnings and Precautions ( 5.2 )] . Accidental Ingestion Accidental ingestion of even one dose of APADAZ, especially by children, can result in a fatal overdose of hydrocodone [see...
What it is approved for
From the label in effect Jan 7, 2025.
APADAZ is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 ) ] reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. APADAZ should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. APADAZ is a combination of benzhydrocodone, a prodrug of the opioid agonist hydrocodone, and acetaminophen, and is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use ( 1 ) Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia APADAZ should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.
Mechanism: Benzhydrocodone Benzhydrocodone is a prodrug of hydrocodone. Hydrocodone Hydrocodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of hydrocodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with hydrocodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- APADAZ · ACETAMINOPHEN 325MG; BENZHYDROCODONE HYDROCHLORIDE EQ 4.08MG BASE · TABLET, ORAL · Discontinued
- APADAZ · ACETAMINOPHEN 325MG; BENZHYDROCODONE HYDROCHLORIDE EQ 8.16MG BASE · TABLET, ORAL · Discontinued
- APADAZ · ACETAMINOPHEN 325MG; BENZHYDROCODONE HYDROCHLORIDE EQ 6.12MG BASE · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Acetaminophen" as an intervention, any sponsor and status, largest first.
OMNI Medical Services, LLCResearch network
NCT03944447 · 200,000 participants (planned) · Start Dec 1, 2018 · Primary completion Dec 31, 2025
Drug: Cannabis, Medical · For: Chronic Pain; Chronic Pain Syndrome; Chronic Pain Due to Injury and 30 more
Sites: Boca Raton, Florida; Bradenton, Florida; Fort Lauderdale, Florida · 17 sites in all
- A Study of a Candidate COVID-19 Vaccine (COV003)Pivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT04536051 · 10,300 participants (planned) · Start Jun 2, 2020 · Primary completion Sep 2021
Drug: ChAdOx1 nCoV-19 single dose + paracetamol; MenACWY single dose + paracetamol and 2 more · For: Coronavirus
Sites: Salvador, Brazil; Natal, Brazil; Porto Alegre, Brazil · 6 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- To Relieve Pain and Anxiety - an Intervention Study in Ambulance ServicesPivotal-lookingCompleted
Sahlgrenska University HospitalAcademic, hospital or other
NCT00792181 · 2,800 participants (planned) · Start Jun 2008 · Primary completion Nov 2008
Drug: Midazolam · For: Acute Myocardial Infarction; Pain
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT04504812 · 1,937 participants · Start Feb 1, 2021 · Primary completion Apr 8, 2025
Drug: Duloxetine · For: Knee Osteoarthritis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 24 sites in all
- Intravenous Acetaminophen for Postoperative Delirium in Older Patients Recovering From Major Noncardiac SurgeryPivotal-lookingNot yet recruiting
RenJi HospitalAcademic, hospital or other
NCT06653465 · 1,930 participants (planned) · Start Jun 2025 · Primary completion Jun 2027
Drug: Acetaminophen; Saline · For: Delirium in Old Age
- Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02183688 · 1,889 participants · Start Sep 1998 · Primary completion Jan 2003
Drug: Low dose ASA; High dose ASA and 4 more · For: Migraine Disorders
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use5
- product dose omission issue5
- urinary tract infection4
- fluid retention3
- kidney infection3
- localised infection3
- peripheral swelling3
- rash3
- skin discomfort3
- condition aggravated2
- decreased appetite2
- diarrhoea2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Short-term Dual Therapy or Mono Therapy With Acetaminophen and Ibuprofen for Fever: A Network Meta-Analysis.
De la Cruz-Mena JE, Veroniki AA, Acosta-Reyes J, et al. · Pediatrics 2024 · Systematic Review, Network Meta-Analysis
- Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis.
Tan E, Braithwaite I, McKinlay CJD, et al. · JAMA Netw Open 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Tramadol (with or without acetaminophen) efficacy and harm: Systematic review and meta-analysis.
Otte JA, Chu G, Heran B, et al. · Can Fam Physician 2025 · Systematic Review, Meta-Analysis
- Acute Postoperative Pain Due to Dental Extraction in the Adult Population: A Systematic Review and Network Meta-analysis.
Miroshnychenko A, Ibrahim S, Azab M, et al. · J Dent Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C, Kelly S, Hsieh SC, et al. · Headache 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative efficacy and safety of acetaminophen, topical and oral non-steroidal anti-inflammatory drugs for knee osteoarthritis: evidence from a network meta-analysis of randomized controlled trials and real-world data.
Zeng C, Doherty M, Persson MSM, et al. · Osteoarthritis Cartilage 2021 · Comparative Study, Research Support, Non-U.S. Gov't
Sponsor: Zevra Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.